What are the treatment recommendations for mycosis fungoides/Sezary syndrome (MF/SS) cutaneous T-cell lymphoma (CTCL) non-Hodgkin lymphoma (NHL)?

Updated: Jun 12, 2019
  • Author: Priyank P Patel, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


The NCCN recommends that patients be treated at specialized centers with expertise in the management of MF/SS. Unlike other non-Hodgkin lymphoma subtypes, MF/SS criteria have not correlated with prognosis, and treatment decisions are made on a clinical basis. [2]

In 2011, the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the EORTC issued a joint consensus statement proposing new clinical end points and response criteria for use in clinical trials of MF/SS. [29] The NCCN includes the new criteria in its current recommendations. [2]

All three guidelines recommend treatment selection based on clinical stage. [26, 27, 2]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!